CD8A and lymphoma: We analyzed a variety of clinical factors (gender, age, risk stratification, clinical stage, CAR-T cell dose, serum peak concentration of IL-6 and CRP, CD4/CD8, etc.)that may be associated with CRS in patients with lymphoma, separately.